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Abstract
Background: Tumor growth is intimately linked with stromal interactions. Myeloid derived suppressor cells (MDSCs) are
dramatically elevated in cancer patients and tumor bearing mice. MDSCs modulate the tumor microenvironment through
attenuating host immune response and increasing vascularization.
Methodology/Principal Findings: In searching for molecular mediators responsible for pro-tumor functions, we found that
regulator of G protein signaling-2 (Rgs2) is highly increased in tumor-derived MDSCs compared to control MDSCs. We
further demonstrate that hypoxia, a common feature associated with solid tumors, upregulates the gene expression.
Genetic deletion of Rgs2 in mice resulted in a significant retardation of tumor growth, and the tumors exhibit decreased
vascular density and increased cell death. Interestingly, deletion of Rgs2 in MDSCs completely abolished their tumor
promoting function, suggesting that Rgs2 signaling in MDSCs is responsible for the tumor promoting function. Cytokine
array profiling identified that Rgs22/2 tumor MDSCs produce less MCP-1, leading to decreased angiogenesis, which could
be restored with addition of recombinant MCP-1.
Conclusion: Our data reveal Rgs2 as a critical regulator of the pro-angiogenic function of MDSCs in the tumor
microenvironment, through regulating MCP-1 production.
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Introduction
It has become clear that the tumor microenvironment plays an
important role in tumor progression. Tumors are comprised of several
host derived cell types, including fibroblasts, smooth muscle cells,
endothelial cells, immune cells, and epithelial cells, each contributing
to the microenvironment in ways we are onlybeginning to understand
[1]. In addition to the cells present, the tumor microenvironment
contains extracellular matrix (ECM) and other factors secreted by the
tumor and stromal cells that can greatly affect tumor progression.
Immune suppression and promotion of angiogenesis are essential
for tumor growth and progression. Interestingly, MDSCs possess
both properties, and create an environment to facilitate tumor
progression. MDSCs increase in tumor bearing hosts, including
cancer patients, and this accumulation is mediated by inflammatory
and angiogenic factors [2]. MDSCs are also known to promote a
shift to a type 2, tumor-promoting response in macrophages [3]. In
addition, they infiltrate into tumors, and promote tumor vascular-
ization, tumor growth, and metastasis through modulating VEGF
bioavailability and protease activity in the tumor microenvironment
[4,5,6,7]. The pro-angiogenic function of these myeloid cells is
sufficient to confer tumor refractoriness to anti-VEGF treatment
[8], a common target for anti-angiogenic therapy. This further
illustrates the importance of MDSCs in tumor progression, as well
as in molecular therapies for cancer.
Rgs2 (NM_009061) is a signaling molecule known to function
downstream of G protein coupled receptors. Rgs2 contains a
conserved Regulator of G protein Signaling domain, and functions
as a GTPase-activating protein (GAP) for several Ga subunits of G
proteins [9,10,11]. Rgs2 is widely expressed in a variety of cells,
including myeloid cells [12,13]. A variety of stimuli can induce
Rgs2 expression, most of which signal through G proteins.
Therefore, Rgs2 functions in a negative feedback loop with regard
to G protein coupled receptors (GPCRs). It enhances the intrinsic
GTPase activity of the Ga subunit, and thereby decreases the time
that the G protein subunits are dissociated, leading to decreased
signaling [14,15]. In addition, cell stress, such as heat shock or
DNA damage, can also increase Rgs2 levels [16,17]. Rgs2 inhibits
cell proliferation, and is a known mediator of cell differentiation in
several cell types, such as myeloid cells [18].
Monocyte chemoattractant protein 1 (MCP-1) is a chemokine
important for cell migration [19,20]. It signals through CCR2, a
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[20,21,22]. In part due to a migratory effect on endothelial cells,
MCP-1 is a potent angiogenic factor, promoting vascularization ex
vivo and in vivo [22]. Blocking MCP-1 with a neutralizing antibody
inhibited angiogenesis, and led to decreased tumor metastases and
increased survival in a mouse tumor model [22].
Here, we report a novel role of Rgs2 in tumor growth and
progression. Rgs2 expression is elevated in tumor derived MDSCs,
and hypoxia, a condition commonly associated with tumors,
upregulates its expression. Inactivation of Rgs2 in MDSCs leads to
a significant reduction of MCP-1, and retards tumor angiogenesis
and tumor progression. Thus, this study identifies Rgs2 as a critical
mediator of pro-angiogenic function associated with MDSCs in
the tumor microenvironment.
Materials and Methods
Ethics
All mouse studies have been conducted according to Animal
Welfare Act and the Public Health Service Policy and approved by
Vanderbilt University Institution Animal Care and Use Commit-
tee (IACUC) (M/05/083). The animals were housed in pathogen-
free units at Vanderbilt University Medical Center, in compliance
with IACUC regulations. Rgs22/2 mice in C57Bl/6 background
were obtained from Dr. Josef Penninger at the Institute of
Molecular Biotechnology GmbH, and were bred at Vanderbilt
University Medical Center. Age and gender matched wild type
control mice were purchased from Jackson Laboratories.
Cell culture
HL-60 and 3LL cell lines (purchased from ATCC) were
cultured in RPMI 1640+10% FBS at 37uC, 5% CO2. The 3LL
cell line is a subclone of LLC (Lewis lung carcinoma) cell line. The
B16 (purchased from ATCC) and MC26 [4] cell lines were grown
in DMEM+10% FBS. Human umbilical vein endothelial cells
(HUVECs) were obtained from Lonza, and cultured in EGM-2
Bulletkit medium, also from Lonza, at 37uC, 5% CO2. HUVECs
were used between passages 3 to 7.
Isolation of lung microvascular cells
Mice were sacrificed, and the chest cavity was opened. The
right ventricle of the heart was punctured with a 25 gauge butterfly
needle and syringe. The heart and lungs were flushed with
PBS+2 mM EDTA until the lungs were white, followed by 0.25%
Figure 1. Induction of Rgs2 in tumor derived MDSCs. (A) Purity of cells from isolation of Gr-1+CD11b+ cells using MACS. Spleens from non-
tumor bearing and MC26 tumor bearing BALB/c mice were isolated and processed into to single cell suspension, followed by sorting using MACS, as
described in the Methods section. (B) and (C) Gr-1+CD11b+ cells were isolated from non tumor bearing and tumor bearing mice, MC26 tumors in
BALB/c (B) and 3LL tumors in C57BL/6 (C), by magnetic sorting of pooled splenocytes from 5–10 mice, generating MDSCs of greater than 98% purity.
Cells were then subjected to RNA isolation and RT-PCR (B) and real time PCR (C) for Rgs2 expression. These experiments were repeated 3 times. (D)
HL-60 cells were incubated under normoxic (20% O2) or hypoxic (1.0–2% O2) conditions for an hour, and RNA was isolated, followed by real time PCR
analysis. This experiment was performed 5 times. (E) HL-60 cells were treated with medium conditioned by 3LL tumor cells for one hour. RNA was
isolated, followed by real time PCR analysis. The experiment was performed 3 times. * p,0.05.
doi:10.1371/journal.pone.0018534.g001
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removed, pumped with more trypsin, and allowed to incubate at
37uC for 20 minutes. The lungs were then diced, and the tissue
was pipetted several times in DMEM + 10% FBS. After
centrifugation, the cell pellet was resuspended in EGM, and
seeded into plates. Medium was changed the next day to remove
cell debris and red blood cells.
RT-PCR
RNA was isolated from cells using the RNeasy kit from Qiagen.
iScript cDNA synthesis kit (BioRad) was used to produce cDNA.
For PCR, Hi-Fidelity PCR mix (Invitrogen) was used, and for Real
Time PCR, SYBR green kit (BioRad) and an iCycler or MyiQ
machine (BioRad) were used.
Tumor model
For tumor growth studies, 3LL or B16 cells were injected
subcutaneously into the left hindlimbs of mice. For the
reconstitution assay, 3LL cells were mixed with MDSCs isolated
by fluorescence activated cell sorting (FACS) and injected as
before. Tumor size was measured by caliper, and tumor volume
was calculated as volume=length6(width)
260.5. Tumor samples
taken at days 17–21 post-injection were flash frozen in OCT
(Sakura) or fixed in formalin and embedded in paraffin, then
sectioned. Sections were incubated with primary antibodies
overnight, then either Texas Red-fluorescent or biotin-labeled
secondary antibodies for immunofluorescent or immunohisto-
chemical analysis, respectively. Slides were imaged on an Olympus
BX51 microscope with an Olympus DP70 camera. Images were
overlaid using Adobe Photoshop.
Flow cytometry, FACS, and MACS
Tissues were prepared into single cell suspensions and labeled
with antibodies for markers of mature and immature blood cells
(BD Biosciences). Cells were analyzed using a BD LSRII or BD
FACScan. For FACS, spleen cells were labeled with Gr-1
Figure 2. Deletion of Rgs2 in MDSCs retards tumor growth. (A) Rgs22/2 and C57BL/6 wild type mice were injected with 5610
5 3LL tumor
cells subcutaneously in the hindlimb, and tumor size was measured by caliper over time (n=12 mice per group). This experiment was repeated 3
times. (B) Wild type mice were injected subcutaneously in the hindlimb with 1610
5 3LL cells alone, or 3LL cells combined with 1610
4 wild type or
Rgs22/2 MDSCs sorted by flow cytometry (.95% purity; data not shown) from spleens of tumor-bearing mice. Tumor growth was measured by
caliper over time. n=8 mice per group. This experiment was performed twice. * p,0.05.
doi:10.1371/journal.pone.0018534.g002
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VA Flow Cytometry Resource.
For magnetic activated cell sorting (MACS) of MDSCs, tumors
were digested with collagenase A (Sigma) and hyaluronidase
(Sigma). Tumor and spleen MDSCs were isolated by sequential
labeling and column isolation with anti-Gr1-PE and anti-PE
multisort beads, then CD11b beads (all from Miltenyi). We
achieved equal to or greater than 98% purity of Gr-1+CD11b+
cells using MACS (Figure 1A).
BrdU incorporation
BrdU incorporation was performed using the BrdU Flow Kit
from BD Biosciences per the manufacturer’s instructions. Briefly,
BrdU was added to endothelial cells at a final concentration of
10 uM. The cells were collected after 2 hours, fixed, and
permeabilized. The cells were then subjected to DNase treatment
at 37uC, followed by labeling with anti-BrdU and analysis by flow
cytometry.
MDSC morphology
MDSCs were isolated from spleens of wild type and Rgs22/2
tumor bearing mice by MACS. The samples were placed on a
slide using a cytospin centrifuge, stained with the Three Step Stain
(Richard Allan Scientific), and analyzed for morphology by a
hematopathologist (M.A. Thompson) in blind fashion.
In vitro angiogenic assays
Endothelial cell migration: Tumor MDSCs were isolated by
MACS and cultured in RPMI with 1% FBS overnight. Transwells
with 8 micron pores (Corning) were coated with fibronectin in
0.1% gelatin at 37uC one hour prior to addition of HUVECs.
Transwells were placed over the cultured MDSCs, and HUVECs
were added in basal RPMI at 1610
5/well and allowed to migrate
for 3.5 hours. Migrated HUVECs were fixed, stained with crystal
violet, and counted in randomly selected fields under microscopy.
Vascular tube formation: MDSCs were isolated by MACS from
tumor tissue, and cultured in EBM (Lonza) plus 1% FBS overnight.
Wells of 48-well plates were coated with Matrigel (BD Bioscience).
HUVECs were suspended in MDSC conditioned medium and
plated over Matrigel at 80,000 cells/well. Tube formation was
scored by counting branch points at 48 and 72 hours.
Cytokine array
MDSCs were isolated from tumor tissues using MACS, and the
cytokine array was performed according to the manufacturer’s
protocol (RayBiotech). The data were analyzed by densitometry,
with each band being normalized to internal controls.
Statistical analysis
Data were averaged and compared using Student’s t test. Error
bars on graphs represent standard error across experiments or mice.
Figure 3. Lack of Rgs2 in endothelial cells does not affect migration, BrdU incorporation, or tube fomation. Lung microvascular
endothelial cells were isolated from lungs of wild type and Rgs22/2 mice and cultured. (A) 1610
5 cells were placed in the top chamber of a
Transwell, and migrated to growth medium for 4 hours. Cells on the bottom of the Transwell (migrated cells) were fixed, stained with crystal violet,
and counted. Experiment was performed 3 times in duplicate. (B) Cells were pulsed with 10 uM BrdU for 2 hours, then collected, processed, and
analyzed by flow cytometry. The average percentages of BrdU positive cells was plotted. Experiment was performed 2 times in duplicate. (C) Cells
were seeded on top of Matrigel in growth medium and allowed to form tube structures for 48 hours. Branch points were counted, and the average
number per field was graphed.
doi:10.1371/journal.pone.0018534.g003
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Rgs2 is dramatically increased in tumor derived MDSCs
It is well documented that MDSCs from tumor bearing mice
function differently from those from non-tumor bearing mice. In an
effort to investigate the mechanism the tumor utilizes to condition
the MDSCs, we examined gene expression on isolated MDSCs
from spleens of BALB/c mice, either tumor bearing or non-tumor
bearing. We achieved greater than 98% purity (Figure 1A). RT-
PCRanalysisshowedasignificantincreaseofRgs2mRNAintumor
derived MDSCs compared to cells from non-tumor hosts in both
MC26 tumor model in BALB/c mice (Figure 1B) and 3LL tumor
model in C57BL/6 mice (Figure 1C). Interestingly, we found a
similar Rgs2 induction in MDSCs associated with MC26 and 3LL
tumor conditions compared to non-tumor conditions by RT-PCR
(Figure 1B–C). Further analysis showed that hypoxia, a feature
commonlyassociated withsolidtumors,significantlyincreasedRgs2
RNA levels in a myeloid cell line in vitro (Figure 1D), consistent with
published studies indicating that Rgs2 may be a stress response
gene, increasing rapidly under conditions which are stressful for the
cell. In addition, treatment with 3LL tumor conditioned medium
led to a significant increase in Rgs2 mRNA levels in myeloid cells,
suggesting that the tumor cells are secreting a factor capable of
modulating Rgs2 expression (Figure 1E). The findings demonstrate
that tumor conditions, such as hypoxia and secreted factors,
upregulate Rgs2 expression in MDSCs.
Rgs2 signaling in MDSCs mediates tumor growth
Because MDSCs of tumor bearing mice upregulate Rgs2
expression, we sought to understand the role Rgs2 plays in
Figure 4. Lack of Rgs2 does not affect populations of mature leukocytes. Spleens were isolated from non-tumor bearing and 3LL tumor
bearing WT and Rgs22/2 mice, processed into single cell suspensions, and labeled with the indicated antibodies, then analyzed by flow cytometry.
Experiment was performed 3 times with 3–4 mice per group.
doi:10.1371/journal.pone.0018534.g004
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without Rgs2 are viable, healthy, and fertile, but have defects in
hippocampal development [23]. Since the Rgs2 null mouse was
developed in the C57Bl/6 background, we injected Rgs22/2
mice and C57BL/6 wild type controls with syngeneic 3LL cells
subcutaneously in the hindlimb, and measured tumor growth
over time. The null mice exhibited significantly retarded tumor
growth compared to the wild type mice (Figure 2A). Similar
results were achieved when the mice were injected with a
syngeneic melanoma tumor line, B16 (data not shown). These
results reveal a positive role of Rgs2 in tumor growth and
progression.
To examine the specific role of Rgs2 in MDSCs, we performed
a reconstitution experiment. MDSCs were isolated from spleens of
tumor bearing wild type or null mice by fluorescence activated cell
sorting using antibodies against Gr-1 and CD11b. We achieved
greater than 95% purity (data not shown). These MDSCs were co-
injected with 3LL cells subcutaneously in the hindlimb of wild type
mice, and tumor growth was measured over time (Figure 2B). We
found that while wild type MDSCs were able to promote tumor
growth, Rgs22/2 MDSCs lost their tumor promoting function,
when compared to growth of the tumor cells alone (Figure 2B).
Furthermore, we evaluated lung microvascular endothelial cells
isolated from WT and Rgs22/2 mice, and found no difference in
Figure 5. Tumors in Rgs22/2 mice exhibit decreased vascular density and increased cell death. (A), (C), (E) Sections from size matched
3LL tumors grown in wild type mice and Rgs2 null mice were stained for CD31, active caspase-3 and PCNA, respectively. Representative images are
shown. (B), (D), (F) The numbers of CD31 positive vascular structures, active caspase-3 positive cells, and PCNA positive cells, respectively, were
quantified in 10 randomly selected fields under microscopy. These experiments were repeated 3–4 times. ** p,0.005, * p,0.05.
doi:10.1371/journal.pone.0018534.g005
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migration in response to serum stimulation between the two
groups (Figure 3). In addition, Rgs2 deficiency did not affect the
proportions of immature hematopoietic populations (data not
shown) or mature hematopoietic populations (Figure 4). Together,
these data support a specific role of Rgs2 signaling in MDSCs that
is responsible for their tumor promoting activity.
Tumors from Rgs22/2 mice exhibit decreased
vascularization and increased cell death
MDSCs are known to infiltrate into tumors and promote
tumor angiogenesis. Histological analysis of size-matched 3LL
tumors from wild type and Rgs22/2 mice revealed a
significantly lower vascular density, as measured by CD31-
positive vessel structures, in tumors harvested from null mice than
from wild type controls (Figure 5A–B). Similar results were
observed when we used another vascular marker, von Willebrand
factor (data not shown). Consistently, there is a significant
increase in cell death, as indicated by cleaved caspase-3 staining
in tumors from the null mice (Figure 5C–D). We did not see any
significant difference in cell proliferation, as measured by PCNA
staining, between the two groups (Figure 5E–F). These findings
point to a pro-angiogenic function of Rgs2 in MDSCs in tumor
growth and progression.
Rgs2 plays no significant role in MDSC expansion and
differentiation
MDSCs are elevated in tumor bearing hosts, and display different
differentiation profiles compared to cells from non-tumor bearing
hosts [4,5,6,7]. Since Rgs2 is elevated in tumor derived MDSCs, we
then determined whether Rgs2 has a role in MDSC expansion by
analyzing spleens from 3LL tumor bearing wild type and null mice by
flow cytometry. We found that spleens of both mice contained similar
numbers of MDSCs (Figure 6A). Next, to determine if the lack of
Rgs2 affects the proportions of the cells that comprise the heterogeneic
Gr-1+CD11b+ fraction, we isolated Gr-1+CD11b+ cells from spleens
of tumor bearing wild type and Rgs22/2 m i c ea n ds c o r e dt h e mb y
morphology (Figure 6B). We observed a small decrease in the more
monocytic MDSCs. However, no other cell types were different.
Furthermore, we analyzed several cell surface molecules, such as
Ly6C and Ly6G, on Gr-1+CD11b+ cells from wild type and
Rgs22/2 mice by flow cytometry, and found no significant
differences (Figure 7). These data indicate that it is less likely that
Rgs2 plays a major role in expansion and differentiation of MDSC.
Rgs2 upregulates MCP-1 in MDSCs
A major function for MDSCs is secretion of growth factors,
contributing to the cytokine milieu that promotes tumor growth.
To determine if lack of Rgs2 affects cytokine production within
Figure 6. Rgs2 deficiency has minimal effects on MDSC expansion and differentiation. (A) Wild type and Rgs22/2 mice were injected
with 1610
5 3LL cells in the hindlimb, and 20 days later, spleens were isolated and analyzed by flow cytometry for Gr-1+CD11b+ MDSCs. This
experiment was performed at least 3 times and the graphs shown are results from pooling of 3 mice per group. (B) MDSCs were isolated from spleens
of tumor bearing Rgs22/2 and wild type mice using the MACS system, spun onto slides using a cytospin centrifuge, and stained. The slides were
read by a hematopathologist in a blind fashion, and cells were categorized by morphology. This experiment was performed 4 times. * p,0.01.
doi:10.1371/journal.pone.0018534.g006
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wild type and null MDSCs isolated directly from 3LL tumor tissue.
We found a dramatic reduction of MCP-1 (,9—10-fold) in Rgs2
null MDSCs compared to wild type MDSCs (Figure 8A). Using
real time RT-PCR on RNA isolated from 3LL tumor tissue-
derived MDSCs, we confirmed that, similar to the cytokine array,
MCP-1 mRNA levels were significantly reduced in Rgs2 null
MDSCs compared to wild type MDSCs (Figure 8B). Moreover,
we measured MCP-1 protein levels by ELISA from media of
cultured MDSCs purified from tumor tissues of wild type and
Rgs22/2 mice for 48 hours. Consistently, we detected a
dramatic reduction in the MCP-1 protein levels produced and
secreted by Rgs22/2 MDSCs compared to wild type cells
(Figure 8C).
In addition, we analyzed a potential correlation of Rgs2 and
MCP-1 mRNA levels in vivo using freshly isolated MDSCs by real
time RT-PCR. Consistent with an induction of Rgs2 in tumor
derived MDSCs, there is a significant increase of MCP-1 levels in
these cells compared to MDSCs isolated from non-tumor bearing
mice (Figure 8D). These results support a positive role of Rgs2 in
regulating MCP-1 expression in MDSCs. Together, the findings
suggest that tumor conditions regulate Rgs2 expression, and Rgs2
regulates MCP-1 expression in MDSCs.
Rgs2 mediates pro-angiogenic function in MDSCs
through MCP-1
MCP-1 is a potent angiogenic factor, and we found that tumors
in Rgs22/2 mice have decreased vascular density compared to
tumors in wild type mice (Figure 5A–B). To determine whether
decreased production of MCP-1 in the null MDSCs is responsible
for defective angiogenesis associated with the Rgs2 null condition,
we performed in vitro angiogenic assays. MDSCs isolated from
tumor tissues of wild type or Rgs22/2 mice were cultivated
overnight. Endothelial cells, (HUVECs) were then cultivated in the
conditioned media from the MDSCs on Matrigel, which allowed
vascular tube structures to form, and branch points were counted
over time. There were significantly fewer vascular structures
developed in the group treated with Rgs22/2 MDSC condi-
tioned medium compared to those treated with wild type MDSC
conditioned medium (Figure 9A and B).
Figure 7. Analysis of cell surface molecules on Gr-1+CD11b+ MDSCs. Spleens were harvested from 3LL tumor bearing WT or Rgs22/2 mice
between days 17–21 post-injection, processed into single cell suspensions, and labeled with antibodies against the indicated cell surface molecules.
Representative plots are shown. Experiment was performed 3 times with 3–4 mice per group. Shaded=WT, open=Rgs22/2.
doi:10.1371/journal.pone.0018534.g007
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toward MDSCs. MDSCs were isolated from the tumor tissues of
wild type and Rgs22/2 mice and cultivated overnight. Then,
HUVECs were seeded in the top Transwell chamber and allowed
to migrate toward the bottom chamber containing the MDSCs. In
agreement with poor vascular tube formation induced by Rgs2
null MDSC conditioned medium, a significant reduction was
observed in endothelial cell migration toward the null MDSCs
compared to wild type cells (Figure 9C). Interestingly, addition of
neutralizing MCP-1 specific antibody significantly inhibited wild
type MDSC mediated endothelial cell migration. The number of
migrated endothelial cells is not statistically different from the
retarded migration observed toward Rgs2 null MDSCs
(Figure 9C). Conversely, addition of recombinant MCP-1 with
the Rgs22/2 MDSCs rescued defective angiogenic function
(Figure 9C). Collectively, these data indicate that MCP-1 is
responsible for Rgs2-mediated pro-angiogenic function in
MDSCs.
Discussion
MDSCs play a critical role in tumor progression through
modulating the tumor microenvironment. They promote tumor
growth at the primary site, as well as enhance metastasis [4,6].
They have been linked to resistance to anti- angiogenic therapy in
cancer [8]. Efforts focused at differentiating or attenuating the
function of MDSCs have been promising, leading to improved
immune response against the tumor and a better prognosis for the
patient [2]. Clearly, identifying molecular mediators important for
MDSC function will enhance our ability to better target these cells
for cancer treatment. In this study, we identified a new mediator,
Rgs2, that regulates pro-angiogenic function of MDSCs. We
found that tumor conditions upregulate Rgs2 expression in
MDSCs, and MDSCs lacking Rgs2 were no longer capable of
promoting tumor growth in tumor reconstitution assays. Tumors
in Rgs22/2 mice grew more slowly, and had less vascular density
and increased cell death.
Furthermore, we identified the downstream molecular mediator
responsible for Rgs2 mediated pro-angiogenic function in MDSCs.
We found that Rgs22/2 MDSCs isolated from tumors produce
drastically reduced levels of MCP-1 compared to wild type. While
MCP-1 has been reported to promote migration of MDSCs
[24,25], production of MCP-1 by MDSCs has previously not been
well studied. MCP-1 is a potent angiogenic factor. It promotes
angiogenesis through indirect effects, such as through monocyte
migration or induction of angiogenic factors such as VEGF and
MMP9 [26,27,28], or by directly functioning on endothelial cells
[22]. In this study, we show that wild type MDSCs secrete MCP-1,
Figure 8. Rgs2 regulates MCP-1 expression in MDSCs. MDSCs were isolated from 3LL tumor tissues of wild type or Rgs22/2 mice by magnetic
sorting after digestion of the tissues with hyaluronidase and collagenase. (A) Protein lysates from the isolated cells were analyzed using a cytokine
array. Each cytokine is detected in duplicate, and intensity was determined using ImageJ software. Positive controls provided on the array were used
for normalization. This experiment was performed twice. (B) RNA was extracted from the isolated MDSCs, and analyzed by real time PCR. Beta-actin
was used as an internal control. This experiment was repeated 3 times. (C) MDSCs were isolated from tumors of wild type and Rgs2 null mice, and
cultured for 48 hours. Culture medium was assayed for MCP-1 protein by ELISA. This experiment was performed in duplicate and repeated 3 times.
*p ,0.05, ** p,0.00005. (D) MDSCs were isolated from normal spleen and 3LL tumor tissues of wild type mice. Rgs2 and MCP-1 levels were measured
by real time PCR. Beta-actin was used as an internal control. This experiment was repeated 2 times. * p,0.05, ** p,0.005.
doi:10.1371/journal.pone.0018534.g008
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formation. Rgs22/2 MDSCs secrete much lower levels of MCP-
1, which leads to reduced angiogenesis in tumors from Rgs22/2
mice.
Together, this study links the tumor promoting roles of Rgs2
in MDSCs to a secreted molecule, MCP-1. We show that
hypoxia, commonly associated with solid tumors, upregulates
Rgs2 expression in MDSCs, which leads to increased production
of MCP-1. The MCP-1 then mediates the angiogenic effects.
MCP-1 is produced mainly under pathological conditions, and is
expressed by several cancer types [28,29]. In a mouse model of
breast cancer, treatment with neutralizing antibodies against
MCP-1 enhanced survival and decreased metastasis [22],
suggesting that targeting of this pathway in human cancer will
likely prove beneficial. While it is uncertain how Rgs2 modulates
MCP-1 levels, Rgs2 was predicted to encode a basic helix-loop-
helix protein [30,31]. Nuclear expression of Rgs2 was reported
in several studies [16,32,33] including our unpublished data.
These findings point to a function of Rgs2 in gene transcription.
Future studies will be necessary to elucidate the mechanism
involved.
In summary, our studies indicate that Rgs2 and MCP-1 are
important molecules for the effector functions of MDSCs. Lack of
Rgs2 in MDSCs abolishes their tumor promoting function, and
leads to decreased levels of MCP-1, along with slower tumor
progression and decreased vascular density in tumors. Thus,
targeting Rgs2 and MCP-1 signaling may have important clinical
implications, and lead to a better prognosis for cancer patients.
Figure 9. Angiogenic function of Rgs2 in MDSC is mediated through MCP-1. (A) and (B) Wild type and Rgs22/2 MDSCs were isolated from
3LL tumor tissues by magnetic sorting, and incubated overnight at 37uC. 80,000 HUVECswere plated in each well of a 48-well plate on top of Matrigel in
the conditioned medium derived from the isolated MDSCs. Representative images are shown at 72 hours, and Vascular network branch points were
scored at the times indicated. This experiment was performed in duplicate and repeated twice. (C) MDSCs were isolated from tumors of Rgs22/2
and wild type mice by magnetic sorting, and incubated overnight. Transwells containing 1610
5 HUVECs in the top chamber were added and
allowed to migrate for 3.5 hours. MCP-1 neutralizing antibody (Ab) (1 ug/ml) was added to wild type cells or 1 ng/ml of recombinant MCP-1 was
added to Rgs22/2 cells. This experiment was performed 3 times in duplicate. * p#0.05, ** p,0.005, *** p,0.001, **** p,0.00005.
doi:10.1371/journal.pone.0018534.g009
Rgs2 Mediates Proangiogenic Function of MDSCs
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18534Acknowledgments
We thank Dr. Laura DeBusk at Vanderbilt University Medical Center for
stimulating discussion and critical comments on the manuscript.
Author Contributions
Conceived and designed the experiments: KCB LEG SJ PCL. Performed
the experiments: KCB LEG MAT LY. Analyzed the data: KCB LEG
MAT LY PCL. Contributed reagents/materials/analysis tools: KCB LEG
SJ MAT LY PCL. Wrote the paper: KCB LEG SJ MAT LY PCL.
References
1. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer
development. Annu Rev Pathol 1: 119–150.
2. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators
of the immune system. Nat Rev Immunol 9: 162–174.
3. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007)
Cross-talk between myeloid-derived suppressor cells and macrophages subverts
tumor immunity toward a type 2 response. J Immunol 179: 977–983.
4. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, et al. (2004)
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing
host directly promotes tumor angiogenesis. Cancer Cell 6: 409–421.
5. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, et al. (2007) Bv8 regulates
myeloid-cell-dependent tumour angiogenesis. Nature 450: 825–831.
6. Yang L, Huang J, Ren X, Gorska AE, Chytil A, et al. (2008) Abrogation of TGF
beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells
that promote metastasis. Cancer Cell 13: 23–35.
7. Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells
in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618–631.
8. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, et al. (2007) Tumor
refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid
cells. Nat Biotechnol 25: 911–920.
9. Druey KM, Blumer KJ, Kang VH, Kehrl JH (1996) Inhibition of G-protein-
mediated MAP kinase activation by a new mammalian gene family. Nature 379:
742–746.
10. Koelle MR, Horvitz HR (1996) EGL-10 regulates G protein signaling in the C.
elegans nervous system and shares a conserved domain with many mammalian
proteins. Cell 84: 115–125.
11. Siderovski DP, Hessel A, Chung S, Mak TW, Tyers M (1996) A new family of
regulators of G-protein-coupled receptors? Curr Biol 6: 211–212.
12. Reif K, Cyster JG (2000) RGS molecule expression in murine B lymphocytes
and ability to down-regulate chemotaxis to lymphoid chemokines. J Immunol
164: 4720–4729.
13. Shi GX, Harrison K, Han SB, Moratz C, Kehrl JH (2004) Toll-like receptor
signaling alters the expression of regulator of G protein signaling proteins in
dendritic cells: implications for G protein-coupled receptor signaling. J Immunol
172: 5175–5184.
14. De Vries L, Zheng B, Fischer T, Elenko E, Farquhar MG (2000) The regulator
of G protein signaling family. Annu Rev Pharmacol Toxicol 40: 235–271.
15. Ross EM, Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G
proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu
Rev Biochem 69: 795–827.
16. Zmijewski JW, Song L, Harkins L, Cobbs CS, Jope RS (2001) Oxidative stress
and heat shock stimulate RGS2 expression in 1321N1 astrocytoma cells. Arch
Biochem Biophys 392: 192–196.
17. Song L, Jope RS (2006) Cellular stress increases RGS2 mRNA and decreases
RGS4 mRNA levels in SH-SY5Y cells. Neurosci Lett 402: 205–209.
18. Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, et al. (2005)
RGS2 is an important target gene of Flt3-ITD mutations in AML and functions
in myeloid differentiation and leukemic transformation. Blood 105: 2107–2114.
19. Rollins BJ, Walz A, Baggiolini M (1991) Recombinant human MCP-1/JE
induces chemotaxis, calcium flux, and the respiratory burst in human
monocytes. Blood 78: 1112–1116.
20. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL (2009) Monocyte
chemoattractant protein-1: a key mediator in inflammatory processes.
Int J Biochem Cell Biol 41: 998–1001.
21. Loetscher P, Seitz M, Baggiolini M, Moser B (1996) Interleukin-2 regulates CC
chemokine receptor expression and chemotactic responsiveness in T lympho-
cytes. J Exp Med 184: 569–577.
22. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, et al. (2000)
Human endothelial cells express CCR2 and respond to MCP-1: direct role of
MCP-1 in angiogenesis and tumor progression. Blood 96: 34–40.
23. Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, et al.
(2000) Regulation of T cell activation, anxiety, and male aggression by RGS2.
Proc Natl Acad Sci U S A 97: 12272–12277.
24. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, et al. (2007) Distinct
roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with
elevated levels of VEGF. Blood 110: 624–631.
25. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, et al. (2008)
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in
tumor-bearing mice. Blood 111: 5457–5466.
26. Goede V, Brogelli L, Ziche M, Augustin HG (1999) Induction of inflammatory
angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 82: 765–770.
27. Varney ML, Olsen KJ, Mosley RL, Singh RK (2005) Paracrine regulation of
vascular endothelial growth factor–a expression during macrophage-melanoma
cell interaction: role of monocyte chemotactic protein-1 and macrophage
colony-stimulating factor. J Interferon Cytokine Res 25: 674–683.
28. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in
tumor growth. Cancer Lett 256: 137–165.
29. Conti I, Rollins BJ (2004) CCL2 (monocyte chemoattractant protein-1) and
cancer. Semin Cancer Biol 14: 149–154.
30. Siderovski DP, Blum S, Forsdyke RE, Forsdyke DR (1990) A set of human
putative lymphocyte G0/G1 switch genes includes genes homologous to rodent
cytokine and zinc finger protein-encoding genes. DNA Cell Biol 9: 579–587.
31. Siderovski DP, Heximer SP, Forsdyke DR (1994) A human gene encoding a
putative basic helix-loop-helix phosphoprotein whose mRNA increases rapidly
in cycloheximide-treated blood mononuclear cells. DNA Cell Biol 13: 125–147.
32. Chatterjee TK, Fisher RA (2000) Cytoplasmic, nuclear, and golgi localization of
RGS proteins. Evidence for N-terminal and RGS domain sequences as
intracellular targeting motifs. J Biol Chem 275: 24013–24021.
33. Song L, Zmijewski JW, Jope RS (2001) RGS2: regulation of expression and
nuclear localization. Biochem Biophys Res Commun 283: 102–106.
Rgs2 Mediates Proangiogenic Function of MDSCs
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18534